Brought to you by 
Roche licenses Memory Pharma's compound to treat Alzheimer's
23 Aug 2021
Executive Summary
Memory Pharmaceuticals (neurological and psychiatric therapeutics) has licensed Roche exclusive worldwide development rights to compounds in preclinical studies to treat Alzheimer's disease. The companies will also co-develop compounds in the same class for other indications including depression and anxiety.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche licenses Memory Pharma's compound to treat Alzheimer's
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice